These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10398105)

  • 61. Moesin and CD44 expression in cutaneous melanocytic tumours.
    Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
    Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression profiles of melanogenesis-related genes and proteins in acquired melanocytic nevus.
    Hashimoto Y; Ito Y; Kato T; Motokawa T; Katagiri T; Itoh M
    J Cutan Pathol; 2006 Mar; 33(3):207-15. PubMed ID: 16466507
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
    Deichmann M; Thome M; Egner U; Hartschuh W; Kurzen H
    J Cutan Pathol; 2005 Aug; 32(7):467-73. PubMed ID: 16008690
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
    Schmid P; Itin P; Rufli T
    Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression of the laminin gamma 2 chain in pancreatic adenocarcinoma.
    Soini Y; Määttä M; Salo S; Tryggvason K; Autio-Harmainen H
    J Pathol; 1996 Nov; 180(3):290-4. PubMed ID: 8958807
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies.
    Kuzbicki L; Lange D; Chwirot BW
    Melanoma Res; 2009 Oct; 19(5):294-300. PubMed ID: 19543125
    [TBL] [Abstract][Full Text] [Related]  

  • 67. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas.
    Pisacane AM; Risio M
    Melanoma Res; 2005 Feb; 15(1):39-43. PubMed ID: 15714119
    [TBL] [Abstract][Full Text] [Related]  

  • 68. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi.
    Itakura E; Huang RR; Wen DR; Paul E; Wünsch PH; Cochran AJ
    Mod Pathol; 2008 Mar; 21(3):326-33. PubMed ID: 18204435
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The use of biomarkers to study pathogenesis and mechanisms of cancer: oesophagus and skin cancer as models.
    Montesano R; Hainaut P; Hall J
    IARC Sci Publ; 1997; (142):291-301. PubMed ID: 9354928
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Expression, function and clinical relevance of MIA (melanoma inhibitory activity).
    Bosserhoff AK; Buettner R
    Histol Histopathol; 2002 Jan; 17(1):289-300. PubMed ID: 11813878
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo.
    Bosserhoff AK; Echtenacher B; Hein R; Buettner R
    Melanoma Res; 2001 Aug; 11(4):417-21. PubMed ID: 11479431
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas.
    Basarab T; Picard JK; Simpson E; Russell-Jones R
    Br J Dermatol; 1999 Jan; 140(1):106-8. PubMed ID: 10215777
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity.
    Miracco C; Margherita De Santi M; Schürfeld K; Santopietro R; Lalinga AV; Fimiani M; Biagioli M; Brogi M; De Felice C; Luzi P; Andreassi L
    Br J Dermatol; 2002 Mar; 146(3):399-408. PubMed ID: 11952539
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas.
    Roesch A; Becker B; Meyer S; Wild P; Hafner C; Landthaler M; Vogt T
    Mod Pathol; 2005 Sep; 18(9):1249-57. PubMed ID: 15803180
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Indices of pigment formation in complex cytomorphological research on human pigmented skin neoplasms].
    Naleskina LA
    Tsitol Genet; 1985; 19(2):83-6. PubMed ID: 3923672
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Melanoma inhibitory activity promotes melanoma development through activation of YBX1.
    Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):685-96. PubMed ID: 23672612
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expression and partial characterization of estramustine-binding protein (EMBP) in human breast cancer and malignant melanoma.
    Björk P; Borg A; Fernö M; Nilsson S
    Anticancer Res; 1991; 11(3):1173-82. PubMed ID: 1888147
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.
    Zhu L; Ito T; Nakahara T; Nagae K; Fuyuno Y; Nakao M; Akahoshi M; Nakagawa R; Tu Y; Uchi H; Furue M
    J Dermatol; 2013 Dec; 40(12):973-9. PubMed ID: 24303922
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma.
    Ramirez RD; D'Atri S; Pagani E; Faraggiana T; Lacal PM; Taylor RS; Shay JW
    Neoplasia; 1999 Apr; 1(1):42-9. PubMed ID: 10935469
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features.
    Pham K; Milovanovic T; Barr RJ; Truong T; Holcombe RF
    Mol Pathol; 2003 Oct; 56(5):280-5. PubMed ID: 14514922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.